S
Sung Yong Kim
Researcher at Soonchunhyang University
Publications - 71
Citations - 724
Sung Yong Kim is an academic researcher from Soonchunhyang University. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 13, co-authored 63 publications receiving 584 citations. Previous affiliations of Sung Yong Kim include Yonsei University & Soonchunhyang University Hospital.
Papers
More filters
Journal ArticleDOI
The prevalence and spectrum of BRCA1 and BRCA2 mutations in Korean population: recent update of the Korean Hereditary Breast Cancer (KOHBRA) study
Eunyoung Kang,Moon Woo Seong,Sue K. Park,Sue K. Park,Jong Won Lee,Jihyoun Lee,Lee Su Kim,Jeong Eon Lee,Sung Yong Kim,Joon Jeong,Sang Ah Han,Sung Won Kim +11 more
TL;DR: The results suggest that the prevalence of BRCA mutations in familial breast cancer patients is similar to that among Western cohorts, however, some single risk factors without family histories may limit the utility of BrcA gene testing in the Korean population.
Journal ArticleDOI
Expression of Programmed Death Receptor Ligand 1 with High Tumor-Infiltrating Lymphocytes Is Associated with Better Prognosis in Breast Cancer
Sang Byung Bae,Hyun Deuk Cho,Mee Hye Oh,Ji-Hye Lee,Si Hyong Jang,Soon Auck Hong,Junhun Cho,Sung Yong Kim,Sun Wook Han,Jong Eun Lee,Han Jo Kim,Hyun Ju Lee +11 more
TL;DR: PD-L1 protein expression in breast cancer is associated with better disease-free survival (DFS) and overall survival (OS) but is not an independent prognostic factor, which has important implications for antibody therapies targeting the PD-1/PD- L1 signaling mechanism in Breast cancer.
Journal ArticleDOI
Expression of survivin and clinical correlation in patients with breast cancer
TL;DR: In this paper, the authors examined the expression patterns of survivin in normal breast tissue, atypical hyperplasia, primary breast cancer and lymph node tissues involved in breast cancer, and determined whether the expression of Survivin is associated with the characteristics and prognosis of breast cancer.
Journal ArticleDOI
Prevalence of BRCA1 and BRCA2 mutations in non-familial breast cancer patients with high risks in Korea: the Korean Hereditary Breast Cancer (KOHBRA) Study.
Byung Ho Son,Sei Hyun Ahn,Sung Won Kim,Eunyoung Kang,Sue K. Park,Min Hyuk Lee,Woo-Chul Noh,Lee Su Kim,Yong Sik Jung,Ku Sang Kim,Dong-Young Noh,Byung In Moon,Young Jin Suh,Jeong Eon Lee,Doo Ho Choi,Sung Yong Kim,Sung Hoo Jung,Cha Kyong Yom,Hy De Lee,Jung-Hyun Yang +19 more
TL;DR: BRCA1/2 mutations for non-familial Korean breast cancer patients were detected at a high rate, particularly, in patients with early onset of less than 35 years of age, bilateral breast cancer, and breast and ovarian cancer.
Journal ArticleDOI
Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial
Hyun-Ah Kim,Jong Won Lee,Seok Jin Nam,Byeong Woo Park,Seock-Ah Im,Eun Sook Lee,Yong Sik Jung,Jung Han Yoon,Sung Soo Kang,Soo Jung Lee,Kyong Hwa Park,Joon Jeong,Se-Heon Cho,Sung Yong Kim,Lee Su Kim,Byung In Moon,Min Hyuk Lee,Tae Hyun Kim,Chanheun Park,Sung Hoo Jung,Geumhee Gwak,Jeryong Kim,Sun Hee Kang,Young Woo Jin,Hee Jeong Kim,Sehwan Han,Wonshik Han,Min Hee Hur,Woo Chul Noh +28 more
TL;DR: The addition of 2 years of OFS to TAM significantly improved DFS compared with TAM alone in patients who remained premenopausal or resumed ovarian function after chemotherapy.